InVivo Therapeutics Enrolls Third Patient in Trial of Biodegradable Scaffold for Spinal Cord Injury

A third spinal cord injury patient has been enrolled inInVivo Therapeutics’pilot clinical trial testing a novel biodegradable scaffold as a therapeutic device for spinal cord injury. The surgery was performed at the Carolinas Medical Center in Charlotte, North Carolina only 3.5 days after the injury. The Neuro-Spinal Scaffold is based on a technology co-invented by Robert Langer from the Massachusetts Institute of Technology in Cambridge, MA and Joseph Vacanti now at the Massachusetts General Hospital in Boston, MA, and is designed to form a substrate for nerve sprouting at the epicenter of the wound. In preclinical studies, the device has helped decrease cyst formation and damage to spinal cord tissue following injury. The current trial will test safety and efficacy of the Scaffold in five patients with acute spinal cord injury as a prelude to a future pivotal study. Although the company’s focus at this stage is spinal cord injury, the platform holds promise for promoting neuronal repair in neurodegenerative diseases, such as ALS and multiple sclerosis.

Click here to read more.

disease-scitbi topic-clinical
Share this: